• FDA is moving to exclude key GLP-1 drugs from its bulk compounding list, putting pressure on Hims & Hers Health's compounded weight-loss offerings.
• Hims & Hers (NYSE:HIMS) is responding by leaning into partnerships for branded GLP-1 medications, including a deal with Novo Nordisk.
• The company is also pushing into international markets through acquisitions such as Australian telehealth provider Eucalyptus.

Hims & Hers Health, trading at $26.33, sits at an interesting point in its story. The stock is up 37.6% over the past 30 days but down 21.2% year to date and 46.8% over the past year. Longer term, the stock’s 3 year and 5 year returns are both described as very large. This pattern may draw attention from investors who are comfortable with sharper swings in sentiment and regulation driven risk.

The FDA’s proposed clampdown on compounded GLP-1 drugs could reshape one of NYSE:HIMS’ faster growing revenue areas and push more volume toward lower margin branded products. The company’s push into partnerships and international expansion signals an effort to keep weight-loss and metabolic health offerings central to its profile while adjusting to a tougher regulatory backdrop.

Stay updated on the most important news stories for Hims & Hers Health by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Hims & Hers Health.

Quick Assessment

• ⚖️ Price vs Analyst Target: At $26.33, Hims & Hers Health trades roughly 1% above the average analyst target of $26.04, sitting inside the consensus range of $18 to $35.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the stock is trading 56.6% below its calculated fair value, flagging it as undervalued.
• ✅ Recent Momentum: The stock is up about 37.6% over the last 30 days, despite regulatory noise around compounded GLP-1s.

There is only one way to know the right time to buy, sell or hold Hims & Hers Health. Head to Simply Wall St's company report for the latest analysis of Hims & Hers Health's Fair Value.

Key Considerations

• 📊 The FDA crackdown puts the higher margin compounded GLP-1 segment under pressure. At the same time, the pivot to branded partnerships and overseas markets reshapes the growth mix.
• 📊 Keep an eye on weight loss revenue share and international revenue contribution from deals like Eucalyptus, as well as whether the 46.8x P/E stays supported by earnings delivery.
• ⚠️ High share price volatility and a high level of debt, alongside compressing profit margins, can amplify any disappointment if partnerships or new markets do not scale as planned.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Hims & Hers Health analysis. Alternatively, you can visit the community page for Hims & Hers Health to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.